Home › Core › ISCC-IDs › 28CCu7Q5S9ShC

View ISCC-ID

Core Data

28CCu7Q5S9ShC
ISCC-ID - digital asset identifier
CCmTyav5CT5ky-CT4tojbnwxpai-CDrYiZNM5KEmD-CRTy7hihAVSb4
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

phase i study of a new ca antagonist sn305lacidipine

Ledger Reference

coblo
Source Ledger/Blockchain
4305
N-th ISCC Decleration on source ledger
24aa9aa32448da449cd5a25cc8456cbeedceb6866141ec3192029948f98df24e
Hash of block that includes the ISCC-DECLARATION
43d4079095df4b78530f3c280edf7da5a8729d1d4de1fa3565ca8c28590f1990
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "Phase I study of a new Ca antagonist, SN305(lacidipine).", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "YUJI KUMAGAI", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://www.jstage.jst.go.jp/article/jscpt1970/22/1/22_1_49/_pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "Japanese Society of Clinical Pharmacology and Therapeutics", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.3999/jscpt.22.49", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCmTyav5CT5ky-CT4tojbnwxpai-CDrYiZNM5KEmD-CRTy7hihAVSb4", "propertyID": "ISCC"}], "datePublished": "1991-01-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close